A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults in Sierra Leone

Trial Profile

A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults in Sierra Leone

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Ad5 EBOV DNA vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms Ad5-EBOV
  • Most Recent Events

    • 30 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 23 Dec 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 17 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top